N@N

ARDEA BIOSCIENCES INC (NASDAQ:RDEA), Up By 5.32% ($1.09) After BUYINS.NET SqueezeTrigger Report Released on Thursday, October 2

^{Published on 2011-10-28 05:43:05 - WOPRAI}
 

October 28, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Thursday, October 27th 2011 at 09:16:00 PDT stating that ARDEA BIOSCIENCES INC (NASDAQ:RDEA) was expected to be Up After it crossed above its SqueezeTrigger Price of 20.43 on Thursday, October 27th 2011. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=rdea&id=204800

From August 2009 to September 2011, an aggregate amount of 22667980 shares of RDEA have been shorted for a total dollar value of $453359600. The RDEA SqueezeTrigger price of $20.43 is the volume weighted average price that all shorts are short in shares of RDEA. There is still approximately $43,630,622 of potential short covering in shares of RDEA.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

ARDEA BIOSCIENCES INC (NASDAQ:RDEA) - Ardea Biosciences, Inc., a biotechnology company, focuses on the discovery and development of small-molecule therapeutics for the treatment of gout, human immunodeficiency virus (HIV), and cancer in the United States. The companys products include RDEA594, a Phase IIb clinical trial product for the treatment of gout; RDEA684, a preclinical trial product for the treatment of gout with hyperuricemia; RDEA806, a non-nucleoside reverse transcriptase inhibitor, which completed Phase II clinical trial for the treatment of patients with HIV; and RDEA427, which is in first-in-human micro-dose pharmacokinetic study for the treatment of HIV infection. It is evaluating RDEA119, an inhibitor of Mitogen-activated ERK kinase (MEK), which is in Phase I/II study in combination with sorafenib and as a single agent in a Phase I study, both in advanced cancer patients. The company has a license agreement with Bayer to develop and commercialize MEK inhibitors for various indications. Ardea Biosciences, Inc. is based in San Diego, California.

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net